PITTSBURGH, PA / April 14, 2014 / NeoStem, Inc. (NASDAQ: NBS) today published a new blog post on The Chairman's Blog, written by the Company's Chairman and CEO Dr. Robin Smith. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Following NeoStem's announced plans to acquire California Stem Cell, Inc. ("CSC"), Dr. Smith reflects on the potential value the transaction will have for the Company. She writes, "Adding CSC's advanced immunotherapy technologies to NeoStem's already diversified development pipeline only adds to our strength in the field." Read the full blog post from Dr. Smith on TheChairmansBlog.com (http://www.thechairmansblog.com/neostem/robin-smith/continued-growth-strategic-acquisitions/).
About NeoStem, Inc.
NeoStem is a leader in the emerging cellular therapy industry, pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. The business includes the development of novel proprietary cell therapy products as well as a revenue-generating contract development and manufacturing service business. This combination has created an organization with unique capabilities for cost effective in-house product development and immediate revenue and cash flow generation. http://www.neostem.com/
TheChairmansBlog.com is an exclusive, online media publication where publicly and privately held firms alike share insights about their companies and industries. TheChairmansBlog.com enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment. http://www.thechairmansblog.com/
SOURCE: NeoStem, Inc. and TheChairmansBlog.com